

Regulatory T Cell Plasticity in Rheumatoid Arthritis: Mechanisms, Pathogenic Roles, and Therapeutic Implications

Faeze Bagherifar¹, Fatemeh Tavassoli Razavi², Mohsen Ghoryani^{1*}

¹ Department of Laboratory Sciences, School of Paramedical Sciences, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran

² Department of Immunology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran

* Corresponding author Email: Ghoryanim1@thums.ac.ir

Received: 2025/9; Revised: 2025/10; Accepted: 2025/10

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent inflammation, progressive joint damage, and functional disability. The plasticity of regulatory T cells (Tregs) plays a central role in the immunopathogenesis of RA by disrupting immune tolerance and promoting pro-inflammatory T helper (Th) 17 (Th17)-like responses. In this review, a comprehensive literature search was conducted in the PubMed, Scopus, and Web of Science databases up to May 2025, using the keywords “rheumatoid arthritis,” “regulatory T cells,” “regulatory T Cell plasticity,” and “immune system regulation.” Reference lists of retrieved publications were manually screened to identify additional relevant studies. Priority was given to peer-reviewed experimental and clinical studies addressing Treg biology, molecular mechanisms of plasticity, and therapeutic implications. Only English-language articles were included, and quality was assessed based on study design, sample size, and reproducibility of findings. Evidence indicates that inflammatory cytokines, metabolic alterations, and epigenetic reprogramming disrupt the stability of forkhead box protein 3 (Foxp3) and promote the conversion of Tregs into Th17-like cells. This shift diminishes suppressive capacity and increases interleukin (IL) 17 (IL-17) production, thereby exacerbating synovial inflammation and joint destruction. Clinical data demonstrate that unstable Foxp3⁺RORγt⁺ Tregs correlate with disease activity and radiographic progression in RA. Current therapeutic strategies—including IL-6 receptor inhibitors, Janus kinase (JAK) inhibitors, rapamycin, and epigenetic modulators—show potential in preserving Treg stability. Moreover, emerging approaches such as chimeric antigen receptor (CAR)-Treg cells and microRNA-based interventions represent innovative directions for targeted immunotherapy. Treg plasticity plays a pivotal role in the pathogenesis of RA and offers novel opportunities for therapeutic intervention. Stabilizing Treg identity and preventing their pathological conversion have the potential to restore immune tolerance, reduce inflammation, and halt disease progression. Clinicians could consider the implications of Treg-targeted strategies as adjuncts to conventional immunomodulatory therapies.

Key words: Rheumatoid arthritis, Regulatory T cells, Regulatory T cell plasticity, Immune system regulation

Introduction

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint inflammation, destruction of cartilage and bone, and motor disability (1). It affects approximately 1% of the global population and is associated with impaired self-tolerance and abnormal activation of the immune system (2). The pathophysiology of RA involves a complex interplay among immune cells, pro-inflammatory cytokines, and dysfunctional regulatory mechanisms, which lead to an immune response against self-antigens (3, 4). Among lymphocyte subsets, regulatory T lymphocytes (Tregs) are recognized as the guardians of self-tolerance; thus, any impairment in their function or numbers plays a crucial role in the initiation and progression of RA (5, 6). Tregs, characterized by the expression of specific markers such as forkhead box protein 3 (Foxp3), CD25, and CD4, play a crucial role in inhibiting autoimmune responses. They achieve this through cell contact-dependent suppressive mechanisms and the secretion of anti-inflammatory cytokines, including interleukin (IL) 10 (IL-10) and transforming growth factor-beta (TGF- β) (7, 8). Recent studies have indicated that in patients with RA, a reduction in the number or functionality of Tregs correlates with an increase in the pathological activity of T helper (Th) 17 lymphocytes (Th17) and the production of pro-inflammatory cytokines such as IL-17 and tumor necrosis factor-alpha (TNF- α). This imbalance between Tregs and Th17 cells is considered a key feature in the pathogenesis of RA (9-13).

An emerging concept in RA immunology is T-cell plasticity, which refers to the ability of these cells to alter their phenotype and function in response to environmental cues (14). Treg plasticity is particularly significant in RA, as under inflammatory conditions, some Tregs may lose their suppressive properties and even transform into pro-inflammatory effector cells (15). This phenomenon not only elucidates the dysfunction of Tregs in RA but also presents a

potential target for immunomodulatory therapies (16, 17). Emerging evidence indicates that environmental factors, such as cytokines, cellular metabolites, and adhesion signals, play a crucial role in regulating Treg plasticity in RA (6, 17, 18).

Evidence Acquisition

Given the critical role of Tregs and their plasticity in the pathophysiology of RA, a more comprehensive understanding of the regulatory mechanisms and factors influencing the differentiation and function of these cells may yield novel therapeutic strategies aimed at restoring immune balance and inhibiting disease progression. In this study, a comprehensive literature search was conducted in the PubMed, Scopus, and Web of Science databases up to May 2025, using the keywords “rheumatoid arthritis,” “regulatory T cells,” “regulatory T Cell plasticity,” and “immune system regulation.” Reference lists of retrieved publications were manually screened to identify additional relevant studies. Priority was given to peer-reviewed experimental and clinical studies addressing Treg biology, molecular mechanisms of plasticity, and therapeutic implications. Only English-language articles were included, and quality was assessed based on study design, sample size, and reproducibility of findings.

Review of Evidence

Tregs: Types and Role of Foxp3

Tregs are a crucial subset of T cells that play a vital role in maintaining self-tolerance and preventing autoimmune responses (8). These cells are categorized into two primary groups: natural Tregs (nTregs) and induced Tregs (iTregs). Natural Tregs differentiate in the thymus and undergo central selection to recognize self-antigens. In contrast, iTregs are generated in the peripheral environment from conventional T cells under the influence of cytokines such as TGF- β and IL-2 (19, 20) (Figure 1).




Figure 1. The primary types of regulatory T cells (Tregs). Tregs are broadly categorized into natural Tregs (nTregs), which develop in the thymus through central selection and are specific for self-antigens, enabling them to maintain immune tolerance, and induced Tregs (iTregs), which differentiate from conventional CD4⁺ T cells in peripheral tissues in response to cytokine signals such as TGF-β and IL-2.

The transcription factor Foxp3 is recognized as a master regulator and marker of Treg function. Stable expression of Foxp3 is crucial for preserving the suppressive phenotype and functional stability of Tregs (21). Research has demonstrated that mutations in the Foxp3 gene result in compromised Treg function and contribute to the development of autoimmune diseases, such as immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX syndrome) (21, 22). Furthermore, Foxp3 plays a vital role in maintaining immune balance by inhibiting the differentiation of pro-inflammatory effector cells, such as Th17 cells (8, 23).

Treg Plasticity: Phenotypic Changes and Pathological Consequences

Treg plasticity refers to the ability of Tregs to alter their phenotype and function in response to environmental signals (14, 18). Under inflammatory conditions, this property can result in the loss of Foxp3 expression and the transformation of Tregs into pro-inflammatory cells. In RA, certain Tregs, influenced by cytokines such as IL-6 and IL-23, can convert into Th17-like cells that secrete IL-17, thereby exacerbating joint inflammation (9, 24) (Figure 2). Treg plasticity not only contributes to the progression of autoimmune diseases but also presents challenges for Treg-based therapies.

However, understanding the mechanisms that regulate plasticity, including metabolic pathways

and epigenetic factors, could offer new strategies to enhance the stability of Tregs (25, 26).




Figure 2. The plasticity and functional instability of regulatory T cells (Tregs) in Rheumatoid Arthritis (RA). In a healthy joint, stable forkhead box protein 3 (Foxp3) expression enables Tregs to suppress inflammation through the production of anti-inflammatory cytokines such as interleukin (IL) 10 (IL-10), transforming growth factor-beta (TGF- β), and IL-35. In RA, chronic inflammation driven by IL-6, IL-23, and tumor necrosis factor-alpha (TNF- α), combined with epigenetic silencing of the Foxp3 promoter, induces Tregs instability. This instability leads to the pathogenic conversion of Foxp3+ T cells into pro-inflammatory, IL-17-producing T helper (Th) 17 (Th17)-like cells, which contribute to joint destruction.

The Inflammatory Joint Environment in RA: Immunological and Metabolic Features

The joints of patients with RA exist in a highly inflamed environment, characterized by the extensive secretion of pro-inflammatory cytokines such as TNF- α , IL-6, IL-1 β , and IL-17. These cytokines not only sustain chronic inflammation but also play a crucial role in the abnormal activation of synovial fibroblast-like cells (FLS) (4, 27). In RA, activated FLS acquire invasive properties and contribute to the progressive destruction of cartilage and bone by

producing matrix metalloproteinases (MMPs) and growth factors (1, 4). Macrophages in RA joints are the primary source of TNF- α and IL-1 β production. These cells enhance T-cell hyperactivation by increasing the expression of costimulatory molecules such as CD80 and CD86. Dendritic cells (DCs) present in the synovial fluid also play a significant role in the expansion of Th17 responses and the reduction of Treg function by presenting self-antigens and producing IL-23 (4, 28). The metabolic environment of the RA joint is characterized by elevated glucose consumption and lactate

accumulation, resulting from the activation of glycolytic pathways in inflammatory cells. These metabolic alterations profoundly affect the function of Tregs. Recent studies have demonstrated that in the hypoxic environment of the RA joint, decreased levels of glutathione and increased reactive oxygen species (ROS) contribute to impaired Treg function (6, 29, 30). Epigenetic changes also contribute to the impairment of Treg function in RA. Hypermethylation of the Foxp3 gene promoter region, along with modifications to histones that regulate the expression of this gene, results in decreased stability of the Treg phenotype. Notably, these epigenetic alterations may be induced by inflammatory cytokines present in the joint environment, promoting the transformation of Tregs into Th17-like cells (28, 31).

Molecular Mechanisms of Treg Plasticity: The Role of Cytokines, Signaling Pathways, and Epigenetic Regulation

The inflammatory environment promotes Treg plasticity towards a Th17 phenotype by modulating the expression of key transcription factors. Research has demonstrated that IL-1 β and IL-6 activate the signal transducers and activators of transcription 3 (STAT3) signaling pathway, leading to the downregulation of Foxp3 expression and the upregulation of retinoic acid-related orphan receptor gamma t (ROR γ t), a transcription factor specific to Th17 cells. Notably, TGF- β at low concentrations, in conjunction with IL-6, facilitates this conversion; however, at high concentrations, it exerts an inhibitory effect (5, 9, 13, 21). These findings indicate that the specific ratio of these cytokines within the microbial environment plays a crucial role in determining the fate of Tregs. At the molecular level, IL-6 induces the phosphorylation of Foxp3 via the STAT3 pathway, resulting in decreased stability of Foxp3. Concurrently, the activation of the ROR γ t pathway initiates the programming of Th17

genes. Recent studies have demonstrated that these alterations are accompanied by epigenetic modifications, including reduced DNA methylation in the promoter region of the RORC gene (which encodes ROR γ t) and increased acetylation of associated histones (4, 9, 31). STAT3, activated by IL-6/IL-23, suppresses Foxp3 and induces ROR γ t, promoting Th17-like conversion. Nuclear factor kappa B (NF- κ B) signaling, sustained by TNF- α , enhances inflammatory gene expression and weakens Treg suppressive function. Hyperactivation of phosphoinositide 3-kinase (PI3K)–protein kinase B (Akt)–mechanistic target of rapamycin (mTOR) (PI3K–Akt–mTOR) links metabolic stress to lineage instability. Together, these pathways integrate cytokine and metabolic cues, amplifying loss of tolerance (32, 33). Additionally, microRNAs (miRs) play a crucial regulatory role in this process. For instance, miR-10a diminishes Foxp3 stability by targeting B-cell lymphoma 6 (BCL-6) and nuclear receptor co-repressor 2 (NCOR2). Conversely, miR-155 inhibits the conversion of Tregs to Th17 cells, highlighting the complex regulatory network of miRs involved in this process. Furthermore, studies have indicated that miR-326 enhances ROR γ t expression by inhibiting E26 transformation-specific sequence-1 (Ets-1) (34, 35). Extensive epigenetic changes occur during the conversion of Tregs to Th17. Hypomethylation of the IL17A enhancer region and hyperacetylation of histone H3 in the promoter region of this gene enhance the accessibility of transcription factors. Furthermore, alterations in the DNA methylation pattern of the Foxp3 gene result in its stable silencing (25, 31, 36). These findings suggest that Treg plasticity relies not only on changes in gene expression but also on enduring epigenetic modifications. In the inflamed synovial microenvironment, hypoxia promotes hypoxia-inducible factor 1-alpha (HIF-1 α)–dependent

glycolysis, which impairs Treg function and facilitates Th17 differentiation. Additionally, increased ROS and altered lipid metabolism further compromise Treg suppressive capacity (37, 38).

Clinical Implications of Treg Plasticity in RA

The plasticity of Tregs and their transformation into Th17-specific cells in RA has significant clinical implications. Studies have demonstrated that the reduction in both the number and function of stable Tregs in RA patients is directly correlated with the severity of the disease and the progression of joint destruction (3, 9, 13, 28). In the inflammatory environment of the RA joint, elevated levels of IL-6 and IL-23 activate the STAT3 pathway and decrease the expression of Foxp3, leading to a loss of regulatory properties and the acquisition of a pro-inflammatory phenotype (4, 9). Analysis of synovial samples from patients with RA has revealed a population of unstable Tregs that co-express Foxp3 and ROR γ t, which is positively correlated with disease activity and radiographic joint damage. These dual-positive cells not only lose their suppressive function but also contribute to chronic inflammation and tissue damage by producing IL-17 (9, 28, 39). From a therapeutic perspective, understanding the mechanisms underlying Treg plasticity has opened new avenues for intervention (36, 39). Epigenetic modulators, such as DNA methyltransferase (DNMT) and Histone deacetylase (HDAC) inhibitors, have demonstrated efficacy in animal models of RA by maintaining Foxp3 stability and preventing the conversion of Tregs to Th17 cells (40-42). Recent findings indicate that targeted therapeutic strategies based on Treg plasticity could help restore immune balance and prevent disease progression. However, significant challenges remain, including the need for accurate methods to identify and isolate stable and unstable Tregs in clinical settings (16, 26, 43). Beyond Treg instability, effector T-cell

resistance to Treg-mediated suppression represents another critical mechanism in RA pathogenesis. Pro-inflammatory cytokines, such as TNF- α and IL-6, along with altered signaling pathways, diminish effector T-cell responsiveness, thereby sustaining inflammation despite the presence of stable Tregs. Therapeutic strategies targeting both Treg stability and effector T-cell sensitivity—such as TNF and IL-6 blockade—may therefore provide synergistic benefits in restoring immune tolerance (44, 45).

Novel Therapeutic Strategies for Regulating the Stability and Plasticity of Tregs

The functional stability of Tregs and the prevention of their undesirable plasticity towards pro-inflammatory phenotypes have been proposed as promising therapeutic strategies for autoimmune diseases, such as RA (17, 26, 38). Recent studies indicate that existing immunomodulatory drugs, including IL-6 receptor inhibitors (tocilizumab) and Janus kinase (JAK) inhibitors (tofacitinib), not only reduce inflammation but also enhance the stability of Tregs by maintaining Foxp3 expression and decreasing ROR γ t expression. These drugs exert their effects by inhibiting the STAT3 pathway, which plays a crucial role in the conversion of Tregs to Th17 cells (46-49). Novel therapeutic approaches that focus on the metabolic modification of Tregs are currently under development. Research has demonstrated that the inhibition of mTOR using rapamycin can enhance the functional stability of Tregs by shifting their metabolic programming from glycolysis to lipid oxidation. Additionally, epigenetic regulators, such as HDAC and DNMT inhibitors, help prevent the transformation of Tregs into pro-inflammatory effector cells by preserving the methylation pattern of the Foxp3 promoter region (50-52). One of the most promising therapeutic strategies is the use of chimeric antigen receptor (CAR)-Treg cells. In this approach, patient-derived Tregs are

engineered with CARs to specifically recognize self-antigens in the joints (53). Preclinical studies have demonstrated that CAR-Tregs are not only more stable in inflammatory environments but also capable of locally suppressing inflammation and preventing joint destruction (54-56). In addition, targeting miRs that regulate Treg plasticity, such as miR-10a and miR-155, has emerged as a promising therapeutic strategy. These approaches can selectively inhibit the signaling pathways involved in the conversion of Tregs to Th17 cells, without compromising the overall suppressive function of the immune system. However, significant challenges remain, including the necessity for tissue-specific targeting systems and precise control of therapeutic dosages (34, 57-59).

Conclusion

A deeper understanding of Treg plasticity has significantly advanced our knowledge of RA pathophysiology. The disruption of Treg stability and their conversion into Th17-like cells play a crucial role in disease initiation and progression. Targeted strategies aimed at preserving Treg function—such as small molecules that enhance Foxp3 stability, CAR-Treg therapy, and epigenetic modulation—hold promise for restoring immune balance. Future research should prioritize the identification of patient-specific biomarkers of Treg stability to enable precision immunotherapy in RA.

References

1. Jahid M, Khan KU, Rehan Ul H, Ahmed RS. Overview of Rheumatoid Arthritis and Scientific Understanding of the Disease. *Mediterr J Rheumatol*. 2023;34(3):284–91.
2. Finckh A, Gilbert B, Hodgkinson B, Bae SC, Thomas R, Deane KD, et al. Global epidemiology of rheumatoid arthritis. *Nat Rev Rheumatol*. 2022;18(10):591–602.
3. Alivernini S, Firestein GS, McInnes IB. The pathogenesis of rheumatoid arthritis. *Immunity*. 2022;55(12):2255–70.
4. D'Orazio A, Cirillo AL, Greco G, Di Ruscio E, Latorre M, Pisani F, et al. Pathogenesis of rheumatoid arthritis: one year in review 2024. *Clin Exp Rheumatol*. 2024;42(9):1707–13.
5. Jiang Q, Yang G, Liu Q, Wang S, Cui D. Function and Role of Regulatory T Cells in Rheumatoid Arthritis. *Front Immunol*. 2021;12:626193.
6. Yan S, Kotschenreuther K, Deng S, Kofler DM. Regulatory T cells in rheumatoid arthritis: functions, development, regulation, and therapeutic potential. *Cell Mol Life Sci*. 2022;79(10):533.
7. Dikiy S, Rudensky AY. Principles of regulatory T cell function. *Immunity*. 2023;56(2):240–55.
8. Grover P, Goel PN, Greene MI. Regulatory T Cells: Regulation of Identity and Function. *Front Immunol*. 2021;12:750542.
9. Chin A, Small A, Wong SW, Wechalekar MD. T Cell Dysregulation in Rheumatoid Arthritis: from Genetic Susceptibility to Established Disease. *Curr Rheumatol Rep*. 2025;27(1):14.
10. Dehnavi S, Shariati-Sarabi Z, Rakhshandeh H, Ghoryani M, Tavakol Afshari J, Mobasheri L, et al. Capparis spinosa significantly improves Th17/Treg imbalance in patients with rheumatoid arthritis: A randomized double blind, placebo-controlled clinical trial in Iran. *J Funct Foods*. 2025;130:106926.
11. Ghoryani M, Shariati-Sarabi Z, Tavakkol-Afshari J, Ghasemi A, Poursamimi J, Mohammadi M. Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: A successful clinical trial in Iran. *Biomed Pharmacother*. 2019;109:1834–40.
12. Ghoryani M, Shariati-Sarabi Z, Tavakkol-Afshari J, Mohammadi M. The Sufficient Immunoregulatory Effect of Autologous Bone Marrow-Derived Mesenchymal Stem Cell Transplantation on Regulatory T Cells in Patients with Refractory Rheumatoid Arthritis. *J Immunol Res*. 2020;2020:3562753.
13. Wang T, Rui J, Shan W, Xue F, Feng D, Dong L, et al. Imbalance of Th17, Treg, and helper innate lymphoid cell in the peripheral blood of patients with rheumatoid arthritis. *Clin Rheumatol*. 2022;41(12):3837–49.
14. Caza T, Landas S. Functional and Phenotypic Plasticity of CD4 (+)T Cell Subsets. *Biomed Res Int*. 2015;2015:521957.
15. Kotschenreuther K, Yan S, Kofler DM. Migration and homeostasis of regulatory T cells in rheumatoid arthritis. *Front Immunol*. 2022;13:947636.
16. Su Q-Y, Li H-C, Jiang X-J, Jiang Z-Q, Zhang Y, Zhang H-Y, et al. Exploring the therapeutic potential of regulatory T cell in rheumatoid arthritis:

Insights into subsets, markers, and signaling pathways. *Biomedicine & Pharmacotherapy*. 2024;174:116440.

17. Zhang J, Liu H, Chen Y, Liu H, Zhang S, Yin G, et al. Augmenting regulatory T cells: new therapeutic strategy for rheumatoid arthritis. *Front Immunol*. 2024;15:1312919.

18. Contreras-Castillo E, García-Rasilla VY, García-Patiño MG, Licona-Limón P. Stability and plasticity of regulatory T cells in health and disease. *J Leukoc Biol*. 2024;116(1):33–53.

19. Owen DL, Sjaastad LE, Farrar MA. Regulatory T Cell Development in the Thymus. *J Immunol*. 2019;203(8):2031–41.

20. Savage PA, Klawon DEJ, Miller CH. Regulatory T Cell Development. *Annu Rev Immunol*. 2020;38:421–53.

21. Georgiev P, Charbonnier LM, Chatila TA. Regulatory T Cells: the Many Faces of Foxp3. *J Clin Immunol*. 2019;39(7):623–40.

22. Barzaghi F, Passerini L. IPEX Syndrome: Improved Knowledge of Immune Pathogenesis Empowers Diagnosis. *Front Pediatr*. 2021;9:612760.

23. Deng G, Song X, Greene MI. FoxP3 in T(reg) cell biology: a molecular and structural perspective. *Clin Exp Immunol*. 2020;199(3):255–62.

24. Blinova VG, Zhdanov DD. Many Faces of Regulatory T Cells: Heterogeneity or Plasticity? *Cells*. 2024;13(11).

25. Carbone F, Colamatteo A, La Rocca C, Lepore MT, Russo C, De Rosa G, et al. Metabolic Plasticity of Regulatory T Cells in Health and Autoimmunity. *J Immunol*. 2024;212(12):1859–66.

26. Goswami TK, Singh M, Dhawan M, Mitra S, Emran TB, Rabaan AA, et al. Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders - Advances and challenges. *Hum Vaccin Immunother*. 2022;18(1):2035117.

27. Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. *Nat Immunol*. 2021;22(1):10–8.

28. Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. *Immunity*. 2017;46(2):183–96.

29. Pucino V, Certo M, Varricchi G, Marone G, Ursini F, Rossi FW, et al. Metabolic Checkpoints in Rheumatoid Arthritis. *Front Physiol*. 2020;11:347.

30. Xu L, Chang C, Jiang P, Wei K, Zhang R, Jin Y, et al. Metabolomics in rheumatoid arthritis: Advances and review. *Front Immunol*. 2022;13:961708.

31. Nemtsova MV, Zaletaev DV, Bure IV, Mikhaylenko DS, Kuznetsova EB, Alekseeva EA, et al. Epigenetic Changes in the Pathogenesis of Rheumatoid Arthritis. *Front Genet*. 2019;10:570.

32. Wang P, Zhang Q, Tan L, Xu Y, Xie X, Zhao Y. The Regulatory Effects of mTOR Complexes in the Differentiation and Function of CD4(+) T Cell Subsets. *J Immunol Res*. 2020;2020:3406032.

33. Wang Z, Xu Z, Zong M, Fan L. Metabolic regulation of Th17 and Treg cell balance by the mTOR signaling. *Metabol Open*. 2025;26:100369.

34. Doghish AS, Ismail A, El-Mahdy HA, Elkhawaga SY, Elsakka EGE, Mady EA, et al. miRNAs insights into rheumatoid arthritis: Favorable and detrimental aspects of key performers. *Life Sciences*. 2023;314:121321.

35. Peng X, Wang Q, Li W, Ge G, Peng J, Xu Y, et al. Comprehensive overview of microRNA function in rheumatoid arthritis. *Bone Res*. 2023;11(1):8.

36. Kleinewietfeld M, Hafler DA. The plasticity of human Treg and Th17 cells and its role in autoimmunity. *Semin Immunol*. 2013;25(4):305–12.

37. Almanzar G, Alarcon JC, Garzon R, Navarro AM, Ondo-Méndez A, Prelog M. Hypoxia and activation of hypoxia inducible factor alpha as influencers of inflammatory helper T cells in autoimmune disease - a link between cancer and autoimmunity. *Front Immunol*. 2025;16:1633845.

38. Rezaei Kahmini F, Shahgaldi S, Azimi M, Mansourabadi AH. Emerging therapeutic potential of regulatory T (Treg) cells for rheumatoid arthritis: New insights and challenges. *Int Immunopharmacol*. 2022;108:108858.

39. Alunno A, Manetti M, Caterbi S, Ibba-Manneschi L, Bistoni O, Bartoloni E, et al. Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications. *Mediators Inflamm*. 2015;2015:751793.

40. Ciechomska M, O'Reilly S. Epigenetic Modulation as a Therapeutic Prospect for Treatment of Autoimmune Rheumatic Diseases. *Mediators Inflamm*. 2016;2016:9607946.

41. Klein K, Ospelt C, Gay S. Epigenetic contributions in the development of rheumatoid arthritis. *Arthritis Res Ther*. 2012;14(6):227.

42. Yang C, Li D, Teng D, Zhou Y, Zhang L, Zhong Z, et al. Epigenetic Regulation in the Pathogenesis of Rheumatoid Arthritis. *Front Immunol*. 2022;13:859400.

43. Esensten JH, Wofsy D, Bluestone JA. Regulatory T cells as therapeutic targets in rheumatoid arthritis. *Nat Rev Rheumatol*. 2009;5(10):560–5.

44. Ge J, Yin X, Chen L. Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations. *Front Immunol*. 2024;15:1457189.

45. Piconese S, Walker LSK, Dominguez-Villar M. Editorial: Control of Regulatory T Cell Stability,

Plasticity, and Function in Health and Disease. *Front Immunol.* 2020;11:611591.

46. Fasching P, Stradner M, Graninger W, Dejaco C, Fessler J. Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders. *Molecules.* 2017;22(1).

47. Kucharz EJ, Stajszczyk M, Kotulska-Kucharz A, Batko B, Brzosko M, Jeka S, et al. Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology. *Reumatologia.* 2018;56(4):203–11.

48. Parisi S, Ditto MC, Ghellere F, Panaro S, Piccione F, Borrelli R, et al. Update on tocilizumab in rheumatoid arthritis: a narrative review. *Front Immunol.* 2025;16:1470488.

49. Schinnerling K, Aguillón JC, Catalán D, Soto L. The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis. *Clin Exp Immunol.* 2017;189(1):12–20.

50. Chen X, Li S, Long D, Shan J, Li Y. Rapamycin facilitates differentiation of regulatory T cells via enhancement of oxidative phosphorylation. *Cell Immunol.* 2021;365:104378.

51. Passerini L, Barzaghi F, Curto R, Sartirana C, Barera G, Tucci F, et al. Treatment with rapamycin can restore regulatory T-cell function in IPEX patients. *J Allergy Clin Immunol.* 2020;145(4):1262–71.e13.

52. Salmond RJ. mTOR Regulation of Glycolytic Metabolism in T Cells. *Front Cell Dev Biol.* 2018;6:122.

53. Ohno R, Nakamura A. Advancing autoimmune Rheumatic disease treatment: CAR-T Cell Therapies - Evidence, Safety, and future directions. *Semin Arthritis Rheum.* 2024;67:152479.

54. Bhandari S, Bhandari S, Bhandari S. Chimeric antigen receptor T cell therapy for the treatment of systemic rheumatic diseases: a comprehensive review of recent literature. *Ann Med Surg (Lond).* 2023;85(7):3512–8.

55. Blagov AV, Pleshko EM, Maltseva ON, Asoyan AZ, Ravani AL, Orekhov AN. CAR-T cell therapy for rheumatoid arthritis: current status and molecular insights. *Cell Mol Biol (Noisy-le-grand).* 2025;71(6):80–8.

56. Múzes G, Sipos F. CAR-Based Therapy for Autoimmune Diseases: A Novel Powerful Option. *Cells.* 2023;12(11).

57. Baumjohann D, Ansel KM. MicroRNA-mediated regulation of T helper cell differentiation and plasticity. *Nat Rev Immunol.* 2013;13(9):666–78.

58. Liu C, Li N, Liu G. The Role of MicroRNAs in Regulatory T Cells. *J Immunol Res.* 2020;2020:3232061.

59. Sethi A, Kulkarni N, Sonar S, Lal G. Role of miRNAs in CD4 T cell plasticity during inflammation and tolerance. *Front Genet.* 2013;4:8.